
Ozempic Shows Promise in Reducing Dementia Risk
A University of Oxford analysis suggests that Novo Nordisk's diabetes drug Ozempic may lower the risk of dementia and nicotine dependence in patients, adding to its known benefits of regulating blood sugar and promoting weight loss. The study, which compared Ozempic to other diabetes treatments, found significant reductions in cognitive problems and nicotine dependence among Ozempic users. However, the findings are observational and need to be confirmed through controlled trials.

